TCR-Engineered T-Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

Scientists discovered Ropporin-1 (ROPN1) as a target to treat triple-negative breast cancer (TNBC) with T-cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues.